Efficacy of Bevacizumab Plus Trifluridine/Tipiracil Based on RAS Mutational Status in Patients With Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer
ESMO Open 2023 Nov 15;8(6)102064, B Doleschal, H Taghizadeh, T Lentner, JM Riedl, J Granitzer, D Morariu, J Decker, KJ Aichberger, G Webersinke, P Kirchweger, A Petzer, H RumpoldFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.